RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $165

Futu NewsJan 7 22:31 · Ratings

RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating

MT NewswiresJan 7 20:31 · Ratings

BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $217

Futu NewsJan 7 08:32 · Ratings

Sarepta Therapeutics (SRPT) Gets a Buy From Bank of America Securities

TipRanksJan 7 08:20 · Ratings

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BusinesswireJan 6 21:30

Sarepta Therapeutics (NASDAQ:SRPT) Delivers Shareholders Respectable 18% CAGR Over 3 Years, Surging 4.2% in the Last Week Alone

Simply Wall StJan 6 21:17